Seeking Alpha
24 Oct 2026, 14:16 UTC · 1h ago
Balchem: Record Sales, Great Fundamentals, Priced Fully, Hold
Impact · against what's priced in
The stock is significantly overvalued despite strong operational performance. While sales growth and cash flow are healthy, a DCF valuation suggests a potential 50% correction to $88 per share.
- BCPC−0.50
No priced-in read yet
- In context
While 8.6% sales growth and $57.9 million in FCF are positive, the DCF valuation of $88 suggests the current $177 price is a 50% overvaluation.
Read from the article alone
- Actual
Top 2 movers · tap to explore
